<version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Quality Measures Clearinghouse (NQMC).</xmlsource>
  <section secid="560" ordby="10" name="General">
    <field fieldid="11" ordby="20" id="561" name="Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Non-Hodgkin lymphoma: percent of patients with lymphoma whose initial lymphoma diagnosis was established by one of the following: incisional or excisional biopsy AND immunohistochemical characterization, OR core needle biopsy AND appropriate ancillary techniques employed.</div>"/>
    </field>
    <field fieldid="1" ordby="30" id="562" name="Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 36 p. </td></tr></table>"/>
    </field>
  </section>
  <section secid="563" ordby="40" name="Measure Domain">
    <field fieldid="3025" ordby="50" id="564" name="Primary Measure Domain" type="picklist-one">
      <fieldvalue value="Clinical Quality Measures: Process"/>
    </field>
    <field fieldid="3026" ordby="60" id="565" name="Secondary Measure Domain" type="picklist-one">
      <fieldvalue value="Does not apply to this measure"/>
    </field>
  </section>
  <section secid="566" ordby="70" name="Brief Abstract">
    <field fieldid="34" ordby="80" id="567" name="Description" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This measure is used to assess the percent of patients with lymphoma whose initial lymphoma diagnosis was established (or confirmed) by one of the following:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Incisional or excisional biopsy of the lymph node AND </li>
    <li>Immunohistochemical characterization
    <p>OR </p>
    </li>
    <li>Core needle biopsy AND </li>
    <li>Appropriate ancillary techniques employed (at least one of the following must have been done)
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Cell phenotype for immunoglobulin heavy chain variable (IgHV) and/or T-cell receptor (TCR) gene rearrangements </li>
        <li>Fluorescence in situ hybridization (FISH) for major translocations (at least one positive result [rearrangement] consistent with a lymphoid neoplasm) </li>
        <li>Immunophenotypic analysis </li>
    </ul>
    </li>
</ul></div>"/>
    </field>
    <field fieldid="21" ordby="90" id="568" name="Rationale" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Support (verbatim) from National Comprehensive Cancer Network (NCCN) guidelines</em>:<br />
In all cases, the most important first step is to make an accurate pathologic diagnosis. The basic pathological evaluation is the same in each guideline though some further evaluation may be useful in certain circumstances to clarify a particular diagnosis.</p>
<p>An incisional or excisional lymph node biopsy is recommended to establish the diagnosis of non-Hodgkin lymphoma (NHL). Core needle biopsy is discouraged unless the clinical situation dictates that this is the only safe means of obtaining diagnostic tissue. Fine needle aspiration (FNA) biopsy is widely used in the diagnosis of malignant neoplasms, but its role in the diagnosis of lymphoma is still controversial. Since the revised Revised European-American Lymphoma (REAL)/World Health Organization (WHO) classification is based on both morphology and immunophenotyping, FNA alone is not acceptable as a reliable diagnostic tool for NHL. However, its use in combination with ancillary techniques may provide precise diagnosis thereby obviating the need for a more invasive biopsy in highly selected circumstances. Recent studies have shown that the diagnostic accuracy of FNA improves significantly when it is used in combination with immunohistochemistry (IHC) and flow cytometry. </p>
<p>In the NCCN guidelines, FNA alone is not suitable for an initial diagnosis of NHL. However, in certain circumstances, when a lymph node is not easily accessible, a combination of core biopsy and FNA in conjunction with appropriate ancillary techniques (polymerase chain reaction [PCR] for immunoglobulin heavy chain variable [IgHV] and/or T-cell receptor [TCR] gene rearrangements; fluorescence in situ hybridization [FISH] for major translocations [at least one positive result (rearrangement) consistent with a lymphoid neoplasm (addition from American Society of Hematology [ASH] Lymphoma Task Force)]; immunophenotypic analysis) may be sufficient for diagnosis. In other entities presenting in leukemic phase, such as follicular lymphoma (FL) or mantle cell lymphoma (MCL), a biopsy is still preferred to clarify histological subtype (NCCN, 2015).</p></div>"/>
    </field>
    <field fieldid="3500" ordby="100" id="569" name="Evidence for Rationale" type="citation">
      <fieldvalue value="<table><tr><td>American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 36 p. </td></tr></table>"/>
      <fieldvalue value="<table><tr><td>National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphoma. Version 12.2016. Fort Washington (PA): National Comprehensive Cancer Network (NCCN); 2015 Nov 24. </td></tr></table>"/>
    </field>
    <field fieldid="3022" ordby="110" id="570" name="Primary Health Components" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Non-Hodgkin lymphoma (NHL); incisional biopsy; excisional biopsy; immunohistochemical characterization; core needle biopsy; immunoglobulin heavy chain variable (IgHV); T-cell receptor (TCR) gene rearrangement testing; fluorescence in situ hybridization (FISH); immunophenotypic analysis</p></div>"/>
    </field>
    <field fieldid="23" ordby="120" id="571" name="Denominator Description" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The number of lymphoma patients in your selection (see the related &quot;Denominator Inclusions/Exclusions&quot; field)</p></div>"/>
    </field>
    <field fieldid="24" ordby="130" id="572" name="Numerator Description" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The number of lymphoma patients in your selection having one of the following:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Incisional or excisional biopsy of the lymph node AND </li>
    <li>Immunohistochemical characterization
    <p>OR </p>
    </li>
    <li>Core needle biopsy AND </li>
    <li>Appropriate ancillary techniques employed (at least one of the following must have been done)
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Cell phenotype for immunoglobulin heavy chain variable (IgHV) and/or T-cell receptor (TCR) gene rearrangements </li>
        <li>Fluorescence in situ hybridization (FISH) for major translocations (at least one positive result [rearrangement] consistent with a lymphoid neoplasm) </li>
        <li>Immunophenotypic analysis </li>
    </ul>
    </li>
</ul>
<p>See the related &quot;Numerator Inclusions/Exclusions&quot; field.</p></div>"/>
    </field>
  </section>
  <section secid="573" ordby="140" name="Evidence Supporting the Measure">
    <field fieldid="3027" ordby="150" id="574" name="Type of Evidence Supporting the Criterion of Quality for the Measure" type="picklist-choice">
      <fieldvalue value="A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence"/>
      <fieldvalue value="One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal"/>
    </field>
    <field fieldid="3501" ordby="160" id="575" name="Additional Information Supporting Need for the Measure" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Statement (verbatim) from research literature on gap</em>:<br />
From the perspective of a clinician attempting to design a treatment plan for patients with lymphoma, we found fine-needle aspiration (FNA) to be woefully inadequate. In 67 patients with both FNA and excisional biopsy done at the time of initial diagnosis, we found 12% concordance. An additional 21% were correctly diagnosed using the broader term of lymphoma, without further histologic subtyping. We consider this group as having an inadequate diagnosis for management. Therefore, 88% of patients were given FNA cytology diagnoses that were clinically inadequate on which to base treatment decisions. More worrisome is our finding that 15% were given a wrong diagnosis (a specific but incorrect histologic subtype). </p>
<p>Those FNAs evaluated with immunophenotyping, in addition to morphology, had a significantly better correlation with excisional biopsy than those FNAs evaluated alone (29% v 2%, respectively; <em>P</em>=.002). Although emphasis is placed on the importance of ancillary techniques, these additional tests were used less than 50% of the time by pathologists in our review. For the initial diagnosis of lymphoma, ancillary techniques were used 41% of the time (Hehn, Grogan, &amp;amp; Miller, 2004). </p>
<p><em>Statement from American Society of Hematology (ASH) Lymphoma Task Force on gap</em>:<br />
This measure has been in use for the American Board of Internal Medicine (ABIM) Maintenance of Certification Performance Improvement Module since July 2013. Performance over the first 10 months (through May 2014) among this highly select group of hematologists is 93%. We believe performance among all hematologists would be somewhat lower. Since accurate diagnosis and staging are the foundation for all treatment, we suggest this gap remains significant.</p></div>"/>
    </field>
    <field fieldid="3502" ordby="170" id="576" name="Evidence for Additional Information Supporting Need for the Measure" type="citation">
      <fieldvalue value="<table><tr><td>American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 36 p. </td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol. 2004 Aug 1;22(15):3046-52. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15284254&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="3072" ordby="180" id="577" name="Extent of Measure Testing" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The non-Hodgkin lymphoma (NHL) measure set was developed by the American Society of Hematology (ASH) using a rigorous methodology (adapted from the American Medical Association [AMA]-convened Physician Consortium for Performance Improvement [PCPI]) and has been field tested. The NHL measure set was accepted by American Board of Internal Medicine (ABIM) for use with practice improvement modules meeting Part 4 of Maintenance of Certification Requirements in 2013.</p></div>"/>
    </field>
    <field fieldid="3007" ordby="190" id="578" name="Evidence for Extent of Measure Testing" type="citation">
      <fieldvalue value="<table><tr><td>Frechette S. (Principal, Northfield Associates, LLC, Warren, VT). Personal communication. 2014 Dec 10. &amp;nbsp;1 p. </td></tr></table>"/>
    </field>
  </section>
  <section secid="580" ordby="210" name="State of Use of the Measure">
    <field fieldid="3029" ordby="220" id="581" name="State of Use" type="picklist-one">
      <fieldvalue value="Current routine use"/>
    </field>
    <field fieldid="3030" ordby="230" id="582" name="Current Use" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
  </section>
  <section secid="583" ordby="240" name="Application of the Measure in its Current Use">
    <field fieldid="3031" ordby="250" id="584" name="Measurement Setting" type="picklist-choice">
      <fieldvalue value="Ambulatory/Office-based Care"/>
    </field>
    <field fieldid="3032" ordby="260" id="585" name="Professionals Involved in Delivery of Health Services" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="3033" ordby="270" id="586" name="Least Aggregated Level of Services Delivery Addressed" type="picklist-one">
      <fieldvalue value="Individual Clinicians or Public Health Professionals"/>
    </field>
    <field fieldid="3505" ordby="280" id="587" name="Statement of Acceptable Minimum Sample Size" type="picklist-one">
      <fieldvalue value="Unspecified"/>
    </field>
    <field fieldid="41" ordby="290" id="588" name="Target Population Age" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="42" ordby="300" id="589" name="Target Population Gender" type="picklist-one">
      <fieldvalue value="Either male or female"/>
    </field>
  </section>
  <section secid="660" ordby="310" name="National Strategy for Quality Improvement in Health Care">
    <field fieldid="3522" ordby="320" id="661" name="National Quality Strategy Aim" type="text">
      <fieldvalue value="<ul><li>Better Care</li></ul>"/>
    </field>
    <field fieldid="3525" ordby="330" id="662" name="National Quality Strategy Priority" type="text">
      <fieldvalue value="<ul><li>Prevention and Treatment of Leading Causes of Mortality</li></ul>"/>
    </field>
  </section>
  <section secid="590" ordby="340" name="Institute of Medicine (IOM) National Health Care Quality Report Categories">
    <field fieldid="3163" ordby="350" id="591" name="IOM Care Need" type="picklist-choice">
      <fieldvalue value="Living with Illness"/>
    </field>
    <field fieldid="3164" ordby="360" id="592" name="IOM Domain" type="picklist-choice">
      <fieldvalue value="Effectiveness"/>
    </field>
  </section>
  <section secid="593" ordby="370" name="Data Collection for the Measure">
    <field fieldid="3506" ordby="380" id="594" name="Case Finding Period" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="3054" ordby="390" id="595" name="Denominator Sampling Frame" type="picklist-one">
      <fieldvalue value="Patients associated with provider"/>
    </field>
    <field fieldid="3057" ordby="400" id="598" name="Denominator (Index) Event or Characteristic" type="picklist-choice">
      <fieldvalue value="Clinical Condition"/>
    </field>
    <field fieldid="3058" ordby="410" id="599" name="Denominator Time Window" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="55" ordby="420" id="596" name="Denominator Inclusions/Exclusions" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Inclusions</strong><br />
The number of lymphoma patients in your selection</p>
<p class=&quot;Note&quot;><strong>Note</strong>: Refer to the original measure documentation for a list of International Classification of Diseases, Tenth Revision (ICD-10) codes used in lymphoma patient selection.</p>
<p><strong>Exclusions</strong><br />
None</p></div>"/>
    </field>
    <field fieldid="3507" ordby="430" id="597" name="Exclusions/Exceptions" type="picklist-choice-4">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="59" ordby="440" id="600" name="Numerator Inclusions/Exclusions" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Inclusions</strong><br />
The number of lymphoma patients in your selection having one of the following:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Incisional or excisional biopsy of the lymph node AND </li>
    <li>Immunohistochemical characterization
    <p>OR </p>
    </li>
    <li>Core needle biopsy AND </li>
    <li>Appropriate ancillary techniques employed (at least one of the following must have been done)
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Cell phenotype for immunoglobulin heavy chain variable (IgHV) and/or T-cell receptor (TCR) gene rearrangements </li>
        <li>Fluorescence in situ hybridization (FISH) for major translocations (at least one positive result [rearrangement] consistent with a lymphoid neoplasm) </li>
        <li>Immunophenotypic analysis </li>
    </ul>
    </li>
</ul>
<p class=&quot;Note&quot;><strong>Note</strong>: This requires documentation in the patient's medical record that the initial lymphoma diagnosis was established by you (or confirmed by you if done by another physician) using an appropriate biopsy as described in the National Comprehensive Cancer Network (NCCN) guidelines. </p>
<p><strong>Exclusions</strong><br />
None</p></div>"/>
    </field>
    <field fieldid="3061" ordby="450" id="601" name="Numerator Search Strategy" type="picklist-one">
      <fieldvalue value="Fixed time period or point in time"/>
    </field>
    <field fieldid="3062" ordby="460" id="602" name="Data Source" type="picklist-many">
      <fieldvalue value="Administrative clinical data"/>
      <fieldvalue value="Paper medical record"/>
    </field>
    <field fieldid="3065" ordby="470" id="603" name="Type of Health State" type="picklist-one">
      <fieldvalue value="Does not apply to this measure"/>
    </field>
    <field fieldid="3066" ordby="480" id="604" name="Instruments Used and/or Associated with the Measure" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
  </section>
  <section secid="605" ordby="490" name="Computation of the Measure">
    <field fieldid="3508" ordby="500" id="606" name="Measure Specifies Disaggregation" type="picklist-one">
      <fieldvalue value="Does not apply to this measure"/>
    </field>
    <field fieldid="3067" ordby="520" id="608" name="Scoring" type="picklist-many">
      <fieldvalue value="Rate/Proportion"/>
    </field>
    <field fieldid="3068" ordby="530" id="609" name="Interpretation of Score" type="picklist-one">
      <fieldvalue value="Desired value is a higher score"/>
    </field>
    <field fieldid="3090" ordby="540" id="610" name="Allowance for Patient or Population Factors" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="3070" ordby="560" id="612" name="Standard of Comparison" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
  </section>
  <section secid="615" ordby="590" name="Identifying Information">
    <field fieldid="73" ordby="600" id="616" name="Original Title" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Measure 1: the percent of patients with lymphoma whose initial lymphoma diagnosis was established by you (or confirmed by you) by one of the following: incisional or excisional biopsy AND immunohistochemical characterization, OR core needle biopsy AND appropriate ancillary techniques employed.</p></div>"/>
    </field>
    <field fieldid="74" ordby="610" id="617" name="Measure Collection Name" type="text">
      <fieldvalue value="Non-Hodgkin Lymphoma Measure Set"/>
    </field>
    <field fieldid="16" ordby="650" id="621" name="Submitter" type="orglist">
      <fieldvalue value="American Society of Hematology - Medical Specialty Society"/>
    </field>
    <field fieldid="17" ordby="660" id="622" name="Developer" type="orglist-p">
      <fieldvalue value="American Society of Hematology - Medical Specialty Society"/>
    </field>
    <field fieldid="79" ordby="670" id="623" name="Funding Source(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The American Society of Hematology </p></div>"/>
    </field>
    <field fieldid="80" ordby="680" id="624" name="Composition of the Group that Developed the Measure" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The American Society of Hematology (ASH) Lymphoma Task Force:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Joseph Connors, MD (<em>Co-Chair</em>) </li>
    <li>Jane Winter, MD (<em>Co-Chair</em>) </li>
    <li>Jonathan Friedberg, MD, MMSc </li>
    <li>Mikkael Sekeres, MD, MS </li>
    <li>Lawrence A. Solberg, Jr., MD, PhD </li>
    <li>Karen Kayoumi (ASH) </li>
    <li>Charles Clayton (ASH) </li>
    <li>Suzanne Leous (ASH) </li>
    <li>Sue Frechette, RN, MBA (Northfield Associates LLC) </li>
    <li>Debra Reis (Healthmonix) </li>
    <li>Lauren Patrick (Healthmonix) </li>
</ul></div>"/>
    </field>
    <field fieldid="81" ordby="690" id="625" name="Financial Disclosures/Other Potential Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="19" ordby="730" id="629" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This measure was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="3086" ordby="740" id="630" name="Date of Most Current Version in NQMC" type="date">
      <fieldvalue value="2017 Feb"/>
    </field>
    <field fieldid="3511" ordby="750" id="631" name="Measure Maintenance" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>American Society of Hematology (ASH) reviews/updates measures annually</p></div>"/>
    </field>
    <field fieldid="3512" ordby="760" id="632" name="Date of Next Anticipated Revision" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="20" ordby="770" id="633" name="Measure Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the measure.</p>
<p>This measure updates a previous version: American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2015 Dec. 36 p. </p></div>"/>
    </field>
    <field fieldid="14" ordby="780" id="634" name="Measure Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Source not available electronically. </p>
<p>For more information, contact the American Society of Hematology (ASH) at 2021 L Street NW, Suite 900, Washington, DC 20036; Phone: 202-776-0544; Fax: 202-776-0545; Web site: <a href=&quot;http://www.hematology.org/&quot; title=&quot;ASH Web site&quot;>www.hematology.org</a>. </p></div>"/>
    </field>
    <field fieldid="87" ordby="800" id="636" name="NQMC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NQMC summary was completed by ECRI Institute on June 19, 2015. The information was verified by the measure developer on August 27, 2015. </p>
<p>This NQMC summary was updated by ECRI Institute on April 18, 2016. The information was verified by the measure developer on May 24, 2016. </p>
<p>This NQMC summary was updated again by ECRI Institute on March 21, 2017. The information was verified by the measure developer on May 3, 2017.</p></div>"/>
    </field>
    <field fieldid="88" ordby="810" id="637" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.</p>
<p>For more information, contact Robert M. Plovnick, MD, MS, Director of Quality Improvement Programs at the American Society of Hematology (ASH), 2021 L Street NW, Suite 900, Washington, DC 20036.</p></div>"/>
    </field>
  </section>
  <section secid="641" ordby="850" name="Production">
    <field fieldid="1" ordby="1366" id="562" name="Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 36 p. </td></tr></table>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NQMC Disclaimer" type="text">
      <fieldvalue value="<p>The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 19:58:22 Jun 24, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 00:44:43 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 34.534 (3)
  esindex: 0.009
  captures_list: 52.948
  CDXLines.iter: 13.364 (3)
  PetaboxLoader3.datanode: 36.291 (4)
  exclusion.robots: 0.213
  exclusion.robots.policy: 0.197
  RedisCDXSource: 1.592
  PetaboxLoader3.resolve: 82.031
  load_resource: 109.731
-->